President Trump Announces Actions to Lower Costs and Expand Access to IVF and Fertility Care
Impact Score: 3.6
Timeline: FDA review expedited to 1-2 months; other timelines depend on market agreements and rulemaking.
Summary: The administration established most-favored-nation pricing with EMD Serono to lower fertility drug costs, providing deep discounts and expecting up to $2,200 savings per IVF cycle. FDA will fast-track lower-cost fertility drugs, and new standalone fertility benefit packages for employers will expand coverage. These actions aim to increase IVF access and support family formation, with significant implications for healthcare providers, employers, and research institutions like Vanderbilt University.
Key Actions: Vanderbilt Medical Center should explore partnerships for MFN pricing; HR to consider fertility benefits for employees; monitor FDA expedited review opportunities; expand fertility research and benefits analysis; assess financial impacts on services and aid programs.
View Full Report
